Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.

Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ.

J Nucl Med. 2014 Nov;55(11):1791-8. doi: 10.2967/jnumed.114.140426. Epub 2014 Oct 23.

2.

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.

Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.

J Nucl Med. 2013 Aug;54(8):1369-76. doi: 10.2967/jnumed.112.116624. Epub 2013 Jun 3.

3.

Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.

Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ.

J Nucl Med. 2017 Feb;58(2):235-242. doi: 10.2967/jnumed.116.178939. Epub 2016 Sep 15.

4.

Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.

Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92. doi: 10.1007/s00259-014-2713-y. Epub 2014 Feb 28.

5.

Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.

Rathke H, Afshar-Oromieh A, Giesel FL, Kremer C, Flechsig P, Haufe S, Mier W, Holland-Letz T, De Bucourt M, Armor T, Babich JW, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Sep;59(9):1373-1379. doi: 10.2967/jnumed.117.200220. Epub 2018 Jan 25.

6.

SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.

Schmidkonz C, Cordes M, Beck M, Goetz TI, Schmidt D, Prante O, Bäuerle T, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.

Clin Nucl Med. 2018 Apr;43(4):225-231. doi: 10.1097/RLU.0000000000001991.

PMID:
29401151
7.

99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.

Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.

Prostate. 2018 Jan;78(1):54-63. doi: 10.1002/pros.23444. Epub 2017 Nov 6.

PMID:
29105797
8.

Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).

Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG.

J Med Chem. 2013 Aug 8;56(15):6108-21. doi: 10.1021/jm400823w. Epub 2013 Jul 22.

9.

99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients.

Santos-Cuevas C, Davanzo J, Ferro-Flores G, García-Pérez FO, Ocampo-García B, Ignacio-Alvarez E, Gómez-Argumosa E, Pedraza-López M.

Nucl Med Biol. 2017 Sep;52:1-6. doi: 10.1016/j.nucmedbio.2017.05.005. Epub 2017 May 25.

PMID:
28575794
10.

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW.

Cancer Res. 2009 Sep 1;69(17):6932-40. doi: 10.1158/0008-5472.CAN-09-1682. Epub 2009 Aug 25.

11.

99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen.

Xu X, Zhang J, Hu S, He S, Bao X, Ma G, Luo J, Cheng J, Zhang Y.

Nucl Med Biol. 2017 May;48:69-75. doi: 10.1016/j.nucmedbio.2017.01.010. Epub 2017 Jan 28.

PMID:
28273495
12.

Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.

Kimura H, Sampei S, Matsuoka D, Harada N, Watanabe H, Arimitsu K, Ono M, Saji H.

Bioorg Med Chem. 2016 May 15;24(10):2251-6. doi: 10.1016/j.bmc.2016.03.051. Epub 2016 Mar 30.

PMID:
27073053
13.

Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.

Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B, Santos-Cuevas C, Azorín-Vega E, Jiménez-Mancilla N, Orocio-Rodríguez E, Davanzo J, García-Pérez FO.

Nucl Med Biol. 2017 May;48:36-44. doi: 10.1016/j.nucmedbio.2017.01.012. Epub 2017 Feb 3.

PMID:
28193503
14.

The Value of 99mTc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients.

Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, Zhang YJ, Ye DW.

Ann Surg Oncol. 2019 Feb;26(2):653-659. doi: 10.1245/s10434-018-6805-y. Epub 2018 Oct 15.

PMID:
30324468
15.

The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.

Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U.

J Nucl Med. 2016 Oct;57(Suppl 3):79S-89S. Review.

16.

Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.

Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.

Prostate. 2017 Aug;77(11):1205-1212. doi: 10.1002/pros.23379. Epub 2017 Jun 26.

PMID:
28649735
17.

99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer.

Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, van Leeuwen FWB, Haller B, Horn T, Heck MM, Gschwend JE, Schwaiger M, Wester HJ, Eiber M.

Eur Urol. 2019 Apr;75(4):659-666. doi: 10.1016/j.eururo.2018.03.013. Epub 2018 Apr 4.

PMID:
29625755
18.

Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection.

Goffin KE, Joniau S, Tenke P, Slawin K, Klein EA, Stambler N, Strack T, Babich J, Armor T, Wong V.

J Nucl Med. 2017 Sep;58(9):1408-1413. doi: 10.2967/jnumed.116.187807. Epub 2017 Mar 16.

19.

Tc-99m-PSMA imaging allows successful radioguided surgery in recurrent prostate cancer.

Kratzik C, Dorudi S, Schatzl M, Sinzinger H.

Hell J Nucl Med. 2018 Sep-Dec;21(3):202-204. doi: 10.1967/s002449910906. Epub 2018 Nov 10.

20.

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U.

J Nucl Med. 2015 Nov;56(11):1697-705. doi: 10.2967/jnumed.115.161299. Epub 2015 Aug 20.

Supplemental Content

Support Center